Squarepoint Ops LLC Takes Position in ICU Medical, Inc. (NASDAQ:ICUI)

Squarepoint Ops LLC purchased a new position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,854 shares of the medical instruments supplier's stock, valued at approximately $3,236,000. Squarepoint Ops LLC owned 0.09% of ICU Medical at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ICUI. Barclays PLC raised its stake in shares of ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock valued at $10,790,000 after buying an additional 8,010 shares during the period. KBC Group NV raised its stake in ICU Medical by 2,498.0% in the 4th quarter. KBC Group NV now owns 17,303 shares of the medical instruments supplier's stock valued at $2,685,000 after acquiring an additional 16,637 shares during the period. OLD National Bancorp IN raised its stake in ICU Medical by 22.0% in the 4th quarter. OLD National Bancorp IN now owns 1,462 shares of the medical instruments supplier's stock valued at $227,000 after acquiring an additional 264 shares during the period. Gagnon Securities LLC raised its stake in ICU Medical by 0.5% in the 4th quarter. Gagnon Securities LLC now owns 28,881 shares of the medical instruments supplier's stock valued at $4,481,000 after acquiring an additional 137 shares during the period. Finally, Jennison Associates LLC bought a new stake in ICU Medical in the 4th quarter valued at about $556,000. Institutional investors own 96.10% of the company's stock.

ICU Medical Price Performance

Shares of ICU Medical stock traded up $5.96 during trading on Thursday, hitting $134.43. 384,189 shares of the stock traded hands, compared to its average volume of 277,797. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of -29.42 and a beta of 0.87. The firm's fifty day moving average is $138.49 and its 200-day moving average is $151.72. ICU Medical, Inc. has a 52 week low of $100.91 and a 52 week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $599.49 million for the quarter, compared to analysts' expectations of $574.15 million. During the same period last year, the business earned $0.96 earnings per share. The business's quarterly revenue was up 6.7% on a year-over-year basis. Research analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Elisha W. Finney sold 600 shares of the firm's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $138.92, for a total transaction of $83,352.00. Following the transaction, the director now directly owns 3,252 shares of the company's stock, valued at approximately $451,767.84. This trade represents a 15.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christian B. Voigtlander sold 5,555 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $135.55, for a total value of $752,980.25. Following the transaction, the chief operating officer now owns 2,389 shares in the company, valued at approximately $323,828.95. The trade was a 69.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,097 shares of company stock valued at $4,860,156 over the last three months. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

ICUI has been the topic of several research reports. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Sunday, May 18th. Raymond James lowered their target price on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. KeyCorp lowered their target price on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ICU Medical presently has an average rating of "Buy" and an average price target of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.